By combining the outcome data with clinicopathological features and multi‐omics data, we could identify multiple prognostic factors for high‐risk DCIS, including high grade, HER2 amplification, and a high burden of DNA copy number aberrations. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.